Premium
EAACI Biologicals Guidelines—dupilumab for children and adults with moderate‐to‐severe atopic dermatitis
Author(s) -
Agache Ioana,
Akdis Cezmi A.,
Akdis Mubeccel,
Brockow Knut,
Chivato Tomas,
Giacco Stefano,
Eiwegger Thomas,
Eyerich Kilian,
GiménezArnau Ana,
Gutermuth Jan,
GuttmanYassky Emma,
Maurer Marcus,
Ogg Graham,
Ong Peck Y.,
O’Mahony Liam,
Schwarze Jürgen,
Warner Amena,
Werfel Thomas,
Palomares Oscar,
Jutel Marek
Publication year - 2021
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/all.14690
Subject(s) - dupilumab , atopic dermatitis , medicine , regimen , health care , medline , intensive care medicine , dermatology , pediatrics , political science , law , economics , economic growth
Atopic dermatitis imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co‐morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of atopic dermatitis, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home‐based), its cost‐effectiveness and long‐term safety. The EAACI Guidelines on the use of dupilumab in atopic dermatitis follow the GRADE approach in formulating recommendations for each outcome and age group. In addition, future approaches and research priorities are discussed.